A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

BACKGROUND: Modified Vaccinia Ankara MVA-BN(®) is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of Modified Vaccinia Ankara MVA-BN(®) (MVA) was assessed in a 56–80 years old population....

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberg, Richard N., Hay, Christine M., Stapleton, Jack T., Marbury, Thomas C., Wagner, Eva, Kreitmeir, Eva, Röesch, Siegfried, von Krempelhuber, Alfred, Young, Philip, Nichols, Richard, Meyer, Thomas P., Schmidt, Darja, Weigl, Josef, Virgin, Garth, Arndtz-Wiedemann, Nathaly, Chaplin, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915701/
https://www.ncbi.nlm.nih.gov/pubmed/27327616
http://dx.doi.org/10.1371/journal.pone.0157335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915701/
https://www.ncbi.nlm.nih.gov/pubmed/27327616
http://dx.doi.org/10.1371/journal.pone.0157335

Ejemplares similares